Paul Sauer is VP at Vaxcyte, Inc. (PCVX). They have made 12 open-market trades across 1 company since 2021, most recently 2022-09-02.
CIK 0001813796
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 12 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| PCVX | 13,822 | $908K |
Shares reported on the most recent Form 4, priced at the 2022-09-07 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| PCVX | SELL | 2022-08-22 | 2022-08-24 | $25.93 | $78K | -5.6% | -9.3% | +61.2% |
| PCVX | SELL | 2022-07-27 | 2022-07-29 | $25.00 | $75K | +15.6% | +22.3% | +80.3% |
| PCVX | SELL | 2022-07-20 | 2022-07-22 | $25.00 | $75K | +7.8% | +14.6% | -2.2% |
| PCVX | SELL | 2022-05-23 | 2022-05-25 | $26.22 | $79K | -22.4% | -23.6% | +4.3% |
| PCVX | SELL | 2022-04-22 | 2022-04-26 | $25.00 | $75K | -2.3% | +4.1% | -5.8% |
| PCVX | SELL | 2022-03-22 | 2022-03-24 | $25.00 | $75K | +5.7% | +6.2% | -15.4% |
| PCVX | SELL | 2022-03-10 | 2022-03-14 | $25.00 | $150K | +0.3% | +4.3% | -25.0% |
| PCVX | SELL | 2021-12-29 | 2021-12-30 | $25.00 | $150K | -6.9% | -24.9% | -5.1% |
| PCVX | SELL | 2021-11-01 | 2021-11-03 | $25.00 | $75K | +4.4% | -22.7% | -23.0% |
| PCVX | SELL | 2021-09-22 | 2021-09-24 | $25.20 | $267K | -7.6% | -12.5% | -6.8% |
| PCVX | SELL | 2021-03-11 | 2021-03-15 | $25.00 | $63K | -9.0% | -26.2% | -14.8% |
| PCVX | SELL | 2021-02-11 | 2021-02-16 | $26.61 | $125K | -12.4% | -4.4% | -28.8% |
| PCVX | SELL · 10b5-1 | 2021-01-11 | 2021-01-12 | $26.21 | $66K | +0.8% | -0.1% | -22.1% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.